Oncology Supportive Care · LP-164
Prednisolone Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-164Oncology Supportive Care
- Generic identity
- PrednisoloneTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-164
- Generic ingredient
- Prednisolone
- Dosage form
- Tablet
- Proposed strength
- 5 mg; 20 mg
- Proposed pack
- Blister 10 x 10 tablets
- Portfolio category
- Oncology Supportive Care
About Prednisolone
Prednisolone is a systemic glucocorticoid used for selected inflammatory, allergic and immune-mediated conditions. It changes inflammatory and immune responses and has effects throughout the body. Its role depends on the diagnosis and the intended duration of exposure. The oral tablet strengths in a catalogue do not establish that the medicine is appropriate for a symptom such as pain, cough or fatigue without clinical assessment.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Professional selection considers disease severity, expected benefit and other treatments. During therapy, clinicians may monitor infection, blood glucose, blood pressure, mood and other effects according to the patient and exposure. Prednisolone is not interchangeable with every other corticosteroid on a milligram-for-milligram basis. This page provides high-level ingredient information and does not provide a tapering schedule, a steroid-equivalence table or candidate-specific approved indications.
Important safety considerations
Infection, hyperglycaemia, mood changes, gastrointestinal complications and adrenal suppression are important concerns. Longer exposure can contribute to osteoporosis, eye disease, muscle weakness and growth effects. Stopping suddenly after substantial exposure can cause adrenal problems and requires professional planning. Diabetes, latent infections, glaucoma, bone risk and interacting medicines need review. Serious infection symptoms or marked psychiatric changes should be assessed promptly.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
This entry concerns oral prednisolone tablets. Enteric coating, soluble properties, salt identity and scoring should not be assumed unless verified. Product-specific excipients and administration characteristics must be checked in the approved leaflet and dossier.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm the diagnosis, exposure plan, infection and metabolic risks, interactions and monitoring. Establish any appropriate steroid-alert documentation and supervised discontinuation plan under local guidance.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Prednisolone
- Dosage form / presentation
- Tablet
- Catalogue strength
- 5 mg; 20 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Portfolio category
- Oncology Supportive Care
Layer 02
Unresolved product-specific fields
- The oral prednisolone tablet record does not establish exact salt/ester form, enteric/soluble character, scoring, crushing suitability or excipient composition.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Prednisolonegovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming exact active chemical form, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-164, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-164.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.